Los Angeles Capital Management
SLNO

Los Angeles Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Los Angeles Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,372
Closed -$1.12M – 2488
2026
Q1 		$1.12M Buy
33,372
+13,703
+70% +$537K ﹤0.01% 646
2025
Q4 		$1.36M Sell
19,669
-3,267
-14% -$179K ﹤0.01% 548
2025
Q3 		$1.55M Buy
22,936
+16,540
+259% +$1.23M 0.01% 575
2025
Q2 		$536K Buy
+6,396
New +$479K ﹤0.01% 844

Los Angeles Capital Management's SLNO Position: Q2 2026 in Review

Los Angeles Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 33,372 shares — an estimated $1.12M sold.

Los Angeles Capital Management first reported a position in SLNO in Q2 2025 and held it in 4 quarters. The position peaked at $1.55M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Los Angeles Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 33,372 Soleno Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Los Angeles Capital Management first reported a position in Soleno Therapeutics in Q2 2025 and held it in 4 quarters.
  • Los Angeles Capital Management's Soleno Therapeutics position peaked at $1.55M in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.